ReviewMedChemComm2017
A review on cell wall synthesis inhibitors with an emphasis on glycopeptide antibiotics.
Review in MedChemComm, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 85 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
85 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Terpenes as bacterial efflux pump inhibitors: A systematic review.Frontiers in pharmacology · 2022Pooled it
- Vancomycin, Daptomycin, Antistaphylococcal β-Lactam, and Trimethoprim-Sulfamethoxazole Monotherapy and Combination Therapy in the Management of Methicillin-ResistantFrontiers in pharmacology · 2022Pooled it
- Multivalent Display of Antimicrobial Peptides on Plant Virus Scaffolds Enhances Killing of Drug-Resistant Bacteria.ACS nano · 2026Article
- Computationally Generated Plant-Derived Berberine-Based Hybrid Compounds as Potential Dual Binders toInternational journal of molecular sciences · 2026Article
- Breaking the antimicrobial resistance dilemma: marine natural products, a treasure trove for the development of new anti-Marine life science & technology · 2026Review
- Host-driven remodelling of theMicrobiology (Reading, England) · 2026Review
- The lytic transglycosylase MltA participates in turnover of septal peptidoglycan inbioRxiv : the preprint server for biology · 2026Article
- Metagenomic profiling reveals distinct signatures of pathogens, antibiotic-resistance genes and human viruses in urban river mouths of the north-western Adriatic coast.Scientific reports · 2026Article
- Antibiotic Mechanisms and Resistance: Molecular Insights and Therapeutic Strategies.Antibiotics (Basel, Switzerland) · 2026Review
- From Membrane Composition to Antimicrobial Strategies: Experimental and Computational Approaches to AMP Design and Selectivity.Small (Weinheim an der Bergstrasse, Germany) · 2026Review
- Genome-wide screening of antibiotic survival genes in Escherichia coli MG1655.BMC microbiology · 2026Article
- Determinants of prescribing behaviour of antibacterial drugs in Europe and use of appropriate nomenclature in the literature.Naunyn-Schmiedeberg's archives of pharmacology · 2026Review
- Comprehensive genetic interaction analysis of the Bacillus subtilis envelope using double-CRISPRi.Cell systems · 2025Article
- Lipid II unlocked: strategies for obtaining a major antibiotic target.Chemical communications (Cambridge, England) · 2025Review
- Expansion of the antibacterial spectrum of symmetrical amino acid-paired antifungal peptides through structural optimization.BMC microbiology · 2025Article
- Comprehensive in vitro and whole-genome characterization of probiotic properties in Pediococcus acidilactici P10 isolated from Iranian broiler chicken.Scientific reports · 2025Article
- Exploring the Role of Berberine as a Molecular Disruptor in Antimicrobial Strategies.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Real Way to Target Gram-Negative Pathogens: Discovery of a NovelJournal of medicinal chemistry · 2025Article
- Discovery of novel DdlA inhibitors in multidrug-resistant Pseudomonas aeruginosa using virtual screening, molecular docking, and dynamics simulations.Scientific reports · 2025Article
- Antibiotics and Opportunities of Their Alternatives in Pig Production: Mechanisms Through Modulating Intestinal Microbiota on Intestinal Health and Growth.Antibiotics (Basel, Switzerland) · 2025Review
25 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cell wall biosynthesis inhibitors (CBIs) have historically been one of the most effective classes of antibiotics. They are the most extensively used class of antibiotics and their importance is exemplified by the β-lactams and glycopeptide antibiotics. However, this class of antibiotics has not received impunity from resistance development. In the wake of this predicament, this review presents the progress of CBIs, especially glycopeptide derivatives as antibiotics to confront antibacterial resistance. The various strategies used for the development of CBIs, their clinical status and possible directions in which this field can evolve have also been discussed.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.